Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination drug consisting of three active pharmaceutical ingredients: - **Interferon beta** (a type I interferon, used as an immunomodulator primarily in the treatment of multiple sclerosis; it works by modulating immune responses, upregulating MHC I expression, and enhancing antiviral and anti-inflammatory pathways)[3][4][7]. - **Interferon gamma** (a type II interferon, used to treat chronic granulomatous disease and other immune disorders; it acts as an immunomodulator by activating macrophages and promoting antigen presentation)[7]. - **Medroxyprogesterone** (a synthetic progestin hormone used for contraception, menstrual disorders, endometriosis, menopausal symptoms, and certain cancers; it acts mainly via the progesterone receptor to inhibit gonadotropin production and ovulation. It also has glucocorticoid receptor activity that can modulate immune responses)[6][8][10]. There is no evidence this specific triple combination is approved or marketed under a unique brand name. Each component has distinct mechanisms of action affecting both the endocrine and immune systems.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on interferon beta + interferon gamma + medroxyprogesterone.